Immunotherapy has been disappointing as treatment for prostate cancer, but a new Columbia trial suggests it has potential for treating metastatic disease.
Studies exploring metformin’s power to prevent prostate cancer progression have been inconclusive. Columbia research now shows that the drug has promise, but only for specific patients.
When all evidence of cancer disappeared from Catherine Spina’s patient after radiation of a single metastasis, she became convinced that radiotherapy may be key to a new treatment approach.
After skin cancer, prostate cancer is the most common cancer diagnosed among men in the United States, and about one in eight men will be diagnosed with the disease during their lifetime.